Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count.

Date publication

septembre 2020

Journal

Clinical case reports

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre , Dr GUERCI-BRESLER Agnès , Pr BROSEUS Julien , Pr GIRODON François

Tous les auteurs :
Divoux M, Plocque A, Sevin M, Voillat L, Feugier P, Guerci-Bresler A, Girodon F, Broséus J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32983494

Résumé

Lenalidomide is efficient in reducing red blood cell transfusion dependency and markedly lowering platelet counts in MDS/MPN-RS-T in the context of major platelet counts.

Mots clés

lenalidomide, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombosis, myeloproliferative syndrome, thrombocytosis